You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
AstraZeneca
McKinsey
Merck
Colorcon

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMODIUM A-D

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Imodium A-d

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075868 Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed National Cancer Institute (NCI) Phase 3 2003-12-01 RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00075868 Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed Radiation Therapy Oncology Group Phase 3 2003-12-01 RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00292344 Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Completed Valeant Pharmaceuticals International, Inc. Phase 4 2004-06-01 Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
NCT00292344 Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Completed The University of Texas Health Science Center, Houston Phase 4 2004-06-01 Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
NCT00360828 Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas Terminated H. Lee Moffitt Cancer Center and Research Institute Phase 2 2006-02-01 Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imodium A-d

Condition Name

Condition Name for Imodium A-d
Intervention Trials
Diarrhea 4
Fecal Incontinence 3
Travelers' Diarrhea 2
Short Bowel Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Imodium A-d
Intervention Trials
Diarrhea 8
Fecal Incontinence 3
Short Bowel Syndrome 2
Dysentery 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imodium A-d

Trials by Country

Trials by Country for Imodium A-d
Location Trials
United States 57
Mexico 6
Denmark 1
Canada 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Imodium A-d
Location Trials
Texas 6
North Carolina 4
California 3
Utah 2
New York 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imodium A-d

Clinical Trial Phase

Clinical Trial Phase for Imodium A-d
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Imodium A-d
Clinical Trial Phase Trials
Completed 8
Terminated 5
Not yet recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imodium A-d

Sponsor Name

Sponsor Name for Imodium A-d
Sponsor Trials
M.D. Anderson Cancer Center 3
McNeil AB 2
Johnson & Johnson Consumer and Personal Products Worldwide 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Imodium A-d
Sponsor Trials
Other 26
Industry 15
NIH 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Johnson and Johnson
Dow
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.